MedKoo Cat#: 535290 | Name: Pivhydrazine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pivhydrazine is a bioactive chemical.

Chemical Structure

Pivhydrazine
Pivhydrazine
CAS#306-19-4

Theoretical Analysis

MedKoo Cat#: 535290

Name: Pivhydrazine

CAS#: 306-19-4

Chemical Formula: C12H18N2O

Exact Mass: 206.1419

Molecular Weight: 206.29

Elemental Analysis: C, 69.87; H, 8.80; N, 13.58; O, 7.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pivhydrazine
IUPAC/Chemical Name
2,2-Dimethylpropanoic acid 2-(phenylmethyl)hydrazide
InChi Key
FWWDFDMCZLOXQI-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H18N2O/c1-12(2,3)11(15)14-13-9-10-7-5-4-6-8-10/h4-8,13H,9H2,1-3H3,(H,14,15)
SMILES Code
CC(C)(C)C(NNCC1=CC=CC=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 206.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bolton GC, Griffiths LA. The metabolic disposition of [14C]pivhydrazine, [14C]mebanazine, and [14C]benzylhydrazine in the rat. Drug Metab Dispos. 1979 Nov-Dec;7(6):388-92. PMID: 43225. 2: RENDTORFF H, HILDEN T. Tersavid in angina pectoris. Acta Med Scand. 1961 Oct;170:439-41. doi: 10.1111/j.0954-6820.1961.tb00257.x. PMID: 14491460. 3: RENDTORFF H, HILDEN T. [Tersavid in angina pectoris]. Ugeskr Laeger. 1961 Jan 13;123:62-3. Danish. PMID: 13740830. 4: MURPHY FM, BARBER JM, KILPATRICK SJ. Tersavid in angina pectoris. A sequential clinical trial. Lancet. 1961 Jan 21;1(7169):139-40. doi: 10.1016/s0140-6736(61)91313-7. PMID: 13726969. 5: ALIMURUNG MM, PAULINO-ABUNDO H, TAN AL, CRUZ PM. MONOAMINE OXIDASE INHIBITOR (TERSAVID) IN CORONARY HEART DISEASE. Angiology. 1963 Sep;14:480-3. doi: 10.1177/000331976301400908. PMID: 14057650. 6: JOST M, GASSER P. [On circulatory studies with Tersavid]. Cardiologia. 1961;38:215-9. German. PMID: 13790800. 7: PITT A, GOBLE AJ. Clinical evaluation of "tersavid", "marplan" and "segontin" in angina pectoris. Med J Aust. 1963 Mar 30;50(1):466-8. PMID: 13943842. 8: MUELLER L. [Angina pectoris. Clinical experiences with Tersavid]. Ther Umsch. 1961 Jan;18:11-2. German. PMID: 13773533. 9: CALATAYUD JB, ORVIS HH, PRANDONI AG. Double-blind evaluation of an iproniazid analog (Ro 4-1634) in the treatment of angina pectoris. J Am Geriatr Soc. 1961 Jun;9:432-6. doi: 10.1111/j.1532-5415.1961.tb01621.x. PMID: 24545458. 10: ABRAMS WB, BECKER MC, LEWIS DW, KILLOUGH JH. Amine oxidase inhibitors in the treatment of angina pectoris; preliminary report on marplan and tersavid. Am J Cardiol. 1960 May;5:634-9. doi: 10.1016/0002-9149(60)90129-6. PMID: 13791562. 11: GASPARY FV, GARCIA TURIELLA R, AEBERHARD H, BRUERA E. [Treatment of the anginal syndrome with tersavid]. Prensa Med Argent. 1960 Jul 15;47:2036-9. Spanish. PMID: 13703840. 12: KALT-EGLI F. [Experiences with "tersavid" in the practice of internal medicine]. Praxis. 1960 Jul 7;49:666. German. PMID: 14404189. 13: PELOSI AM. [The use of Tersavid in angina pectoris]. Hospital (Rio J). 1961 Mar;59:607-13. Portuguese. PMID: 13734023. 14: GRANT AP. The use of sequential analysis in preliminary studies of "tersavid" in the treatment of angina pectoris. Ir J Med Sci. 1960 Oct;418:466-72. doi: 10.1007/BF02945636. PMID: 13707867. 15: GALICER RF. [Treatment of pain of cardiac origin with Ro 4-1634, 1-pivaloyl-2-benzylhydrazine]. Sem Med. 1960 Jul 28;117:322-5. Spanish. PMID: 13703071. 16: DIGHIERO J, HAZAN J, RUDOLF J. [Clinical study of a derivative of iproniazid, tersavid, in the treatment of angina pectoris]. Prensa Med Argent. 1960 Mar 25;47:756-9. Spanish. PMID: 13722851. 17: WEISMAN SJ, WEISMAN SA. Tersavid (RO 4-1634), an amine oxidase inhibitor, for the treatment of angina pectoris. Up to 15 months follow-up study. Dis Chest. 1961 Apr;39:459-63. PMID: 13784031.